HC Wainwright started coverage on shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) in a research note released on Wednesday, July 19th, MarketBeat reports. The brokerage issued a buy rating and a $10.00 target price on the specialty pharmaceutical company’s stock.
A number of other analysts have also recently commented on the stock. ValuEngine cut shares of Agile Therapeutics from a sell rating to a strong sell rating in a research note on Friday, June 2nd. Cantor Fitzgerald upped their price target on shares of Agile Therapeutics from $7.00 to $8.00 and gave the company an overweight rating in a research note on Tuesday, April 4th. Royal Bank Of Canada set a $8.00 price target on shares of Agile Therapeutics and gave the company a buy rating in a research note on Sunday, July 16th. Finally, Noble Financial restated a buy rating on shares of Agile Therapeutics in a research note on Wednesday, June 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $9.08.
Shares of Agile Therapeutics (NASDAQ AGRX) traded up 1.75% on Wednesday, hitting $3.49. 165,120 shares of the stock traded hands. The stock’s market cap is $100.53 million. Agile Therapeutics has a 52 week low of $1.82 and a 52 week high of $8.15. The stock has a 50 day moving average price of $4.06 and a 200-day moving average price of $3.28.
Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.02. During the same quarter in the previous year, the firm earned ($0.29) EPS. On average, equities research analysts forecast that Agile Therapeutics will post ($1.05) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/08/15/hc-wainwright-initiates-coverage-on-agile-therapeutics-inc-agrx-updated-updated-updated.html.
Institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC raised its position in shares of Agile Therapeutics by 209.2% in the fourth quarter. Renaissance Technologies LLC now owns 64,000 shares of the specialty pharmaceutical company’s stock worth $365,000 after buying an additional 43,300 shares during the last quarter. Royce & Associates LP raised its position in shares of Agile Therapeutics by 206.1% in the first quarter. Royce & Associates LP now owns 987,582 shares of the specialty pharmaceutical company’s stock worth $3,165,000 after buying an additional 665,000 shares during the last quarter. Susquehanna International Group LLP bought a new position in shares of Agile Therapeutics during the second quarter worth approximately $205,000. Royal Bank of Canada raised its position in shares of Agile Therapeutics by 608.0% in the second quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock worth $122,000 after buying an additional 27,907 shares during the last quarter. Finally, Goldman Sachs Group Inc. bought a new position in shares of Agile Therapeutics during the second quarter worth approximately $309,000. 67.40% of the stock is currently owned by hedge funds and other institutional investors.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
